Friday, November 20, 2026 Vol. I · No. 8
Health · Via STAT

STAT+: Early results for Alterome’s KRAS drug for pancreas, lung and colon cancer arrive

Image: STAT

Alterome presented preliminary Phase 1 results of its drug “selectively” targeting a range of KRAS mutations — drivers of cancers in the pancreas, lung and colon:

This is a brief. The reporting belongs to STAT — read the complete story, with full context and credits, at the source.

Read the full story at STAT ↗

statnews.com

More from the Health desk